Chinese scientists publish “antidote” for ADE from COVID vaccines

There’s two new studies – one that explains how the COVID-19 vaccines are beginning to cause ADE and what is happening. The second is a proposed antidote.

So first, the original study. They’re not calling it ADE. They’re calling it, “ Antibody Dependent Auto-Attack (ADAA)”.

 The current study revealed the pathogenic roles and the new mechanism of action (ADAA) of certain antibodies specific to the spike proteins of coronaviruses such as the COVID-19 virus and the SARS-CoV virus (Figure 8). We had discovered that in a mouse model, pre-injection of anti-influenza immune sera induced more severe infections than the mice infected with an influenza virus alone . Wang and co-workers reported that anti-SARS-CoV spike antisera promoted SARS infection through antibody-dependent enhancement (ADE) in vitro.

Liu and co-workers reported that anti-SARS-CoV spike immune sera induced by a SARS-CoV vaccine caused acute lung injury by promoting MCP1 and IL-8 production and monocyte or macrophage recruitment and accumulation in SARS-CoV infected macaque models.

The previously reported mechanism of action (MOA) of these anti-spike antibodies is ADE-based, in that the antibodies enhance viral infectivity.


Abstract Open PDF

“This study, using a virus-free mouse model, explores the pathogenic roles of certain antibodies specific to the spike proteins of highly pathogenic coronaviruses such as the COVID-19 and the SARS-CoV viruses. Our data showed that these pathogenic antibodies, through a mechanism of Antibody Dependent Auto-Attack (ADAA), target and bind to host vulnerable cells or tissues such as damaged lung epithelium cells, initiate a self-attack immune response, and lead to serious conditions including ARDS, cytokine release, and death. Moreover, the pathogenic antibodies also induced inflammation and hemorrhage of the kidneys, brain, and heart. Furthermore, the pathogenic antibodies can bind to unmatured fetal tissues and cause abortions, postpartum labors, still births, and neonatal deaths of pregnant mice. Novel clinical interventions, through disrupting the host-binding of these pathogenic antibodies, can be developed to fight the COVID-19 pandemic. In addition, the new concept of ADAA explored by this study may be applicable to other infectious diseases, such as the highly pathogenic influenza infections. It should be noted that the majority of anti-spike antibodies are non-pathogenic, as only 2 of 7 monoclonal antibodies tested showed significant pathogenic effects.”
Translate »
Exit mobile version